MISSISSAUGA, ON, April 26,
2022 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical
technologies company, today announced that Ron Hebert has joined the Company as Senior Vice
President of Marketing.
"We are so pleased to welcome Ron to Covalon," said Brian Pedlar, Chief Executive Officer of
Covalon. "With the addition of Ron to our senior leadership team,
we gain a highly creative and driven executive with strong
experience in growth-focused marketing. Ron's experience
engaging with physicians and clinicians in the United States, combined with his past
successes in the biologics, physician services, pediatric,
hematology, and anesthesiology markets, brings strong value to
Covalon's growing infection prevention and advanced wound care
business. Ron will be an asset to our Company as we
grow."
Mr. Hebert brings nearly 30 years of healthcare sales,
marketing, and hospital experience to Covalon. He has extensive
experience leading national and international marketing operations
within prominent global pharmaceutical and medical device
companies, such as Bayer Diagnostics and Beckman Coulter. Prior to joining the Company,
he served as Vice President of Marketing and Communications at
VIVEX Biologics, a regenerative medicine technology company based
in Florida. He also served as Vice
President and Head of Growth Marketing and Sales Operations at
MEDNAX (NYSE: MD) Health Solutions, a $3.5
billion Physician Services Organization. There, he was
responsible for developing and executing the organization's growth
strategies, marketing, communications, and sales operations for
partner hospitals, health systems, and the more than 350
company-owned physician practices under various organizational
sub-brands. Prior to MEDNAX, Mr. Hebert served as the Director of
Global Product Management and Strategy for Beckman Coulter, a Danaher Company, where he
oversaw all global upstream marketing, research and development,
and general management of its $700
million hematology, hemostasis, and urinalysis business.
About Covalon
Covalon Technologies Ltd. is a researcher, developer,
manufacturer, and marketer of patent-protected medical products
that improve patient outcomes and save lives in the areas of
advanced wound care, infection management and surgical procedures.
Covalon leverages its patented medical technology platforms and
expertise in two ways: (i) by developing products that are sold
under Covalon's name; and (ii) by developing and commercializing
medical products for other medical companies under development and
license contracts. The Company is listed on the TSX Venture
Exchange, having the symbol COV and trades on the OTCQX Market
under the symbol CVALF. To learn more about Covalon, visit our
website at www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results, the
impact and timing of COVID-19 on operating activities and market
conditions, and other risks, any of which could cause
results, performance, or achievements to differ materially from the
results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific
to the Company. Investors should consult the Company's ongoing
quarterly filings for additional information on risks and
uncertainties relating to these forward-looking statements.
Investors should not place undue reliance on any forward-looking
statements. The Company assumes no obligation to update or alter
any forward-looking statements whether as a result of new
information, further events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-announces-new-senior-vice-president-of-marketing-301532638.html
SOURCE Covalon Technologies Ltd.